BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31673902)

  • 1. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model.
    Han Y; Yan T; Ma H; Yao X; Lu C; Li Y; Li L
    Dig Dis Sci; 2020 Jun; 65(6):1679-1688. PubMed ID: 31673902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
    Xie F; Luo N; Lee HP
    World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
    Kowada A
    Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of
    Kowada A
    Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
    [No Abstract]   [Full Text] [Related]  

  • 5. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
    Kowada A; Asaka M
    Helicobacter; 2021 Oct; 26(5):e12837. PubMed ID: 34278663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
    Mason J; Axon AT; Forman D; Duffett S; Drummond M; Crocombe W; Feltbower R; Mason S; Brown J; Moayyedi P;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):559-68. PubMed ID: 11876711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
    Ma J; Yu M; Shao QQ; Yu XC; Zhang C; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Chen Q; Jia BL; Chen CL; Lu H; Ding SZ
    Helicobacter; 2022 Aug; 27(4):e12911. PubMed ID: 35706404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
    Wang Q; Jin PH; Lin GW; Xu SR; Chen J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):135-9. PubMed ID: 12697117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
    Kowada A
    Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer.
    Fendrick AM; Chernew ME; Hirth RA; Bloom BS; Bandekar RR; Scheiman JM
    Arch Intern Med; 1999 Jan; 159(2):142-8. PubMed ID: 9927096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of the Helicobacter Pylori Screening Programme in an Asymptomatic Population in China.
    Feng T; Zheng Z; Xu J; Cao P; Gao S; Yu X
    Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.
    Kowada A
    Epidemiol Infect; 2018 Oct; 146(14):1834-1840. PubMed ID: 30056808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis.
    Lee YC; Chiang TH; Chou CK; Tu YK; Liao WC; Wu MS; Graham DY
    Gastroenterology; 2016 May; 150(5):1113-1124.e5. PubMed ID: 26836587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
    Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
    Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.
    Teng AM; Kvizhinadze G; Nair N; McLeod M; Wilson N; Blakely T
    BMC Infect Dis; 2017 Feb; 17(1):156. PubMed ID: 28219322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
    Zhang C; Qi YB; Hu RB; Xu L; Li XT; Ma J; Shao QQ; Abdun MA; Ur Rahman I; Shi WJ; Li FQ; Yu JJ; Yuan MK; Chen Q; Lu H; Ding SZ
    Helicobacter; 2024; 29(3):e13063. PubMed ID: 38874128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.
    Høgh MB; Kronborg C; Hansen JM; Schaffalitzky de Muckadell OB
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1013-1025. PubMed ID: 30854700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations.
    Bae SE; Choi KD; Choe J; Kim SO; Na HK; Choi JY; Ahn JY; Jung KW; Lee J; Kim DH; Chang HS; Song HJ; Lee GH; Jung HY
    Helicobacter; 2018 Apr; 23(2):e12464. PubMed ID: 29345408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.
    Parsonnet J; Harris RA; Hack HM; Owens DK
    Lancet; 1996 Jul; 348(9021):150-4. PubMed ID: 8684154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.